[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chinese SLE Treatment And Research Group\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":309},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,43,71,98,119,141,168,190,213,239,262,287],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100641232","phase-2-sirolimus-in-patients-with-systemic-lupus-erythematosus-associated-immune-thrombocytopenia-100641232",false,"NCT07657793","Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia","A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial and Open-Label Extension Study of Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia","Inclusion Criteria:\n\nAge ≥ 18 and \\\u003C 65 years\n\n1. Meet 2012 SLICC or 2019 EULAR\u002FACR criteria for systemic lupus erythematosus\n2. Meet ITP diagnostic criteria: platelet count ≤ 30×10\\^9\u002FL, or ≤ 50×10\\^9\u002FL with bleeding tendency\n3. At least two CBC tests showing thrombocytopenia\n4. Bone marrow smear showing megakaryocyte maturation disorder\n5. Willing to sign informed consent form\n\nExclusion Criteria:\n\n1. Other causes of thrombocytopenia\n2. Refractory SLE-ITP (no partial response after 3 months of high-dose steroids or immunosuppressants)\n3. Use of rituximab within 6 months\n4. Severe organ involvement (e.g., proteinuria \\> 1g\u002F24h, CNS involvement, cardiac\u002FGI involvement)\n5. Other autoimmune diseases (except Sjögren's syndrome)\n6. Malignancy\n7. Active infections (HIV, HBV, HCV, syphilis)\n8. Severe liver or kidney dysfunction\n9. Splenomegaly\n10. Pregnancy or breastfeeding\n11. Contraindications to study drugs\n12. Unhealed major wounds or incisions\n13. Judged unsuitable by investigator","ALL","18 Years","65 Years",{"count":20,"type":21},164,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","The goal of this clinical trial is to learn if sirolimus, added to standard background therapy (corticosteroids and hydroxychloroquine), works to treat systemic lupus erythematosus-associated immune thrombocytopenia (SLE-ITP) in adults aged 18 to 65 years. The study also aims to evaluate the long-term effectiveness and safety of sirolimus over 48 weeks.\n\nThe main questions it aims to answer are:\n\n1. Does sirolimus increase the overall response rate (complete or partial remission of thrombocytopenia) at 24 weeks compared with placebo?\n2. The safety issues when taking sirolimus over 24 weeks (Phase 1) and up to 48 weeks (Phase 2).\n3. How long does the treatment effect last, and what is the relapse rate during open-label extension? In Phase 1 (first 24 weeks), researchers will compare sirolimus to a placebo (an identical-looking capsule containing no active drug) to see if sirolimus works to treat SLE-ITP when both groups also receive standardized prednisone and hydroxychloroquine. In Phase 2 (weeks 24 to 48), all participants will receive open-label sirolimus to assess long-term efficacy and safety.\n\nParticipants will:\n\n1. Phase 1: Take sirolimus (1.5 mg once daily) or a placebo for 24 weeks, plus standardized prednisone (tapered according to protocol) and hydroxychloroquine (0.4 g daily)\n2. Phase 2: After completing Phase 1, take open-label sirolimus (1.5 mg once daily) for an additional 24 weeks, continuing stable or tapering doses of prednisone and hydroxychloroquine\n3. Visit the clinic at screening, baseline, weeks 4, 12, 24 (end of Phase 1), and then at weeks 28, 36, and 48 (end of Phase 2) for checkups, blood tests, and disease activity assessments\n4. Receive telephone follow-ups at weeks 8, 16, 20, 32, 40, and 44 to report platelet counts, medication adherence, and adverse events",[28,29],"Systemic Lupus Erythematosus","Immune Thrombocytopenia","RECRUITING","2026-06-15",{"date":33,"type":34},"2026-06-18","ACTUAL",{"date":36,"type":34},"2026-06-07",{"date":38,"type":21},"2029-09-30",{"name":40,"class":41},"Chinese SLE Treatment And Research Group","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100642746","phase-4-treatment-strategy-for-patients-with-ra-ild-100642746","NCT07643038","Treatment Strategy for Patients With RA-ILD","Treatment Strategy for Patients With Rheumatoid Arthritis Associated Interstitial Lung Disease","Inclusion Criteria:\n\n* Fulfillment of the 2010 ACR\u002FEULAR classification criteria for RA.\n* HRCT findings consistent with interstitial lung disease (ILD), including ground-glass opacities, reticular abnormalities, fibrotic linear opacities, traction bronchiectasis, or other compatible features, with pulmonary infection, cardiogenic pulmonary edema, and alveolar hemorrhage excluded. The extent of ILD involvement must be ≥20% on HRCT, as assessed by central review.\n* Pulmonary function impairment defined as forced vital capacity (FVC) \\\u003C80% of predicted and\u002For diffusing capacity of the lung for carbon monoxide (DLCO) \\\u003C70% of predicted.\n* Participants receiving glucocorticoids prior to enrollment must be on a stable dose of prednisone ≤10 mg\u002Fday (or equivalent) for at least 4 weeks before baseline.\n* Participants receiving a csDMARD prior to enrollment must be on a stable regimen for at least 4 weeks before baseline.\n* Able and willing to provide written informed consent and comply with study requirements, including scheduled visits and follow-up assessments.\n\nExclusion Criteria:\n\n* Presence of other autoimmune diseases.\n* Presence of severe, uncontrolled clinically significant organ dysfunction or other medical conditions that, in the investigator's judgment, would place the participant at unacceptable risk.\n* History of malignancy within 5 years prior to screening.\n* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study period.\n* Known hypersensitivity to tocilizumab, telitacicept, methotrexate, or any of their excipients.\n* Active hepatitis B or C virus infection, active tuberculosis, active herpes zoster infection, or a history of serious infection within 12 weeks prior to study treatment initiation (defined as an infection requiring hospitalization or intravenous antimicrobial therapy).\n* Severe hypoalbuminemia or serum immunoglobulin G (IgG) level \\\u003C6 g\u002FL.\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3 × the upper limit of normal (ULN), total bilirubin \\>1.5 × ULN, or creatinine clearance (CrCl) \\\u003C60 mL\u002Fmin.\n* Participation in another interventional clinical trial within 4 weeks prior to screening.\n* Inability to adequately perform pulmonary function testing or other study-related assessments.\n* Any other condition that, in the opinion of the investigator, would make the participant unsuitable for participation in this study.","80 Years",{"count":52,"type":21},204,[54],"PHASE4","This is a 52-week, multicenter, prospective, open-label, randomized controlled clinical study, comparing the efficacy and safety of tocilizumab, telitacicept, and csDMARD methotrexate in patients with RA-ILD.",[57],"Rheumatoid Arthritis Associated Interstitial Lung Disease",[59,60,61],"randomized controlled trial","Telitacicept","Tocilizumab","NOT_YET_RECRUITING",{"date":64,"type":34},"2026-06-11",{"date":66,"type":21},"2026-07-01",{"date":68,"type":21},"2029-07-31",{"name":40,"class":41},22,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100627671","phase-4-efficacy-and-safety-of-vunakizumab-and-ivarmacitinib-in-the-treatment-of-active-takayasus-arteritis-100627671","NCT07451665","Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis","A Prospective, Open-label, Controlled, Multiple Centers Clinical Study of the Efficacy and Safety for Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis (TAK): The VIVA-TAK Ttrial","VIVA-TAK","Inclusion Criteria:\n\n* a. Adult patients (aged between 18-70 years) fulfilling the 2022 ACR\u002FEULAR classification criteria for TAK with new-onset or relapsing disease.\n* b. Presence of active disease despite treatment with gluccorticoids combined with a conventional synthetic or biologic immunosuppressive agent other than JAK inhibitors and IL-17 inhibitors, including new-onset patients and relapsed patients.\n\nPatient is considered to have active disease by the investigator is the patients meets at least two of the following three criteria: i) one or more clinical manifestations determined by the investigator to be due to active TAK; ii) one or more findings on imaging of progressive disease; or iii) elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Clinical criteria included constitutional symptoms (fever, fatigue, and weight loss), musculoskeletal symptoms, vascular pain, neurological or visual symptoms, abdominal pain or angina, new or worsening limb claudication, loss of pulses, and worsening hypertension. Imaging criteria includes new vascular stenosis or aneurysms detected by ultrasound, computed tomography angiography (CTA), or magnetic resonance angiography.\n\nExclusion Criteria:\n\n* Participants are excluded from the study if any of the following criteria apply:\n\n  1. Medical Conditions\n\n     1. Severe disease from TAK for which urgent treatment with interventional vascular procedures or bypass surgery is considered necessary\n     2. Critical organ involvement of TAK, such as myocardial or coronary artery involvement, or cerebral ischemia, that is anticipated to need treatment during the study\n     3. Active hepatitis B or C virus infection\n     4. Active tuberculosis (Patients with latent tuberculosis infection could be enrolled with preventive therapy for tuberculosis flare)\n     5. Malignancy in the past 5 years (with the exception of fully excised non-melanoma skin cancer or cervical carcinoma in situ)\n     6. Poorly controlled diabetes\n     7. Patients with history of venous thrombosis\n     8. Upper GI bleeding within 3 months prior to enrollment\n     9. Uncontrolled heart failure\n     10. Refractory hypertension\n  2. Abnormal Laboratory Test Findings k. Serum liver enzyme elevation 3 times higher than the upper limits of normal range l. Severe renal function impairment with estimated glomerular filtration rate ≤ 30 ml\u002Fminute\u002F1.73 m2, calculated using the Modification of Diet in Renal Disease equation (doi:10.1056\u002FNEJMoa2102953)\n  3. Other Exclusion Criteria m. Females who are pregnant or intend to be pregnant during the time frame of the study n. History of treatment with JAKi or IL-17i. o. Any other medical, psychiatric, and\u002For social reason as determined by the investigator to be a contraindication for study participation","70 Years",{"count":81,"type":21},180,[54],"This is a prospective, open-label, controlled, multiple centers, randonmized clinical trial. It compares the clinical efficacy and safety of vunakizumab ivarmacitinib and glucocorticoids in the treatment of active Takayasu's arteritis.",[85],"Takayasu Arteritis (TAK)",[87,88,59],"Vunakizumab","Ivarmacitinib","2026-02-28",{"date":91,"type":34},"2026-03-05",{"date":93,"type":21},"2026-04-01",{"date":95,"type":21},"2029-03-31",{"name":40,"class":41},20,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100622272","phase-4-efficacy-and-safety-of-il-1-inhibitors-in-mild-to-moderate-systemic-lupus-erythematosus-100622272","NCT07381465","Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus","Efficacy and Safety of IL-1 Inhibitors in the Treatment of Mild to Moderate Systemic Lupus Erythematosus With Inadequate Response to Conventional Therapy: A Single-Centre, Single-Arm, Pilot Study","Inclusion Criteria:\n\n* Aged 18 to 65 years, male or female; female participants must not be pregnant or breastfeeding and must agree to use effective contraception during the trial period.\n* Meets the 2012 SLICC classification criteria for SLE or the 2019 ACR\u002FEULAR classification criteria for SLE;\n* Mild to moderate disease activity, 1 point ≤ SLEDAI ≤ 12 points (cSLEDAI ≠ 0);\n* The presence of at least one of the following recent clinical manifestations: fever (excluding fever caused by infection, tumor, endocrine or metabolic disorders, central nervous system diseases, medications, or physical factors), serositis (such as pericarditis or pleurisy), arthritis, rash, or alopecia;\n* ESR or CRP exceeds the upper limit of normal, i.e. ESR \\> 20 mm\u002Fh or CRP \\> 10 mg\u002FL;\n* Patients had received standard therapy prior to study drug administration: ≤1 immunosuppressive agent for at least 12 weeks (methotrexate ≤15 mg\u002Fweek, azathioprine ≤100 mg\u002Fday, mycophenolate mofetil ≤1.5 g\u002Fday, tacrolimus ≤2 mg\u002Fday, cyclosporine ≤150 mg\u002Fday, sirolimus ≤1.5 mg\u002Fday); Hydroxychloroquine (HCQ) may be used; Patients previously treated with biologics (e.g., Belimumab, Telitacicept, Anifrolumab) with inadequate response may also be considered for inclusion, provided they undergo a washout period of three half-lives during screening.\n* The patient voluntarily participated in this trial, demonstrated good compliance, and possessed the capacity to understand and sign the informed consent form prior to the study.\n\nExclusion Criteria:\n\n* SLE with major organ dysfunction, including impaired consciousness, cognitive decline, renal insufficiency, cardiac insufficiency (NYHA class 3 or 4), pulmonary hypertension, and pulmonary interstitial disease.\n* Active SLE organ involvement, including but not limited to active lupus encephalopathy, active lupus nephritis (proteinuria ≥1g\u002F24h), cardiac involvement, gastrointestinal involvement, diffuse alveolar haemorrhage, thrombocytopenic purpura, hemophagocytic syndrome, and retinopathy.\n* SLE coexisting with other autoimmune diseases potentially affecting efficacy assessment, including but not limited to rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.\n* Abnormal liver function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 1.5 times the upper limit of normal; total bilirubin (TBIL) \\> 1 times the upper limit of normal.\n* Any active malignancy or history of malignancy within the preceding five years.\n* Concurrent conditions requiring glucocorticoid therapy, such as asthma or Crohn's disease.\n* Acute or chronic infections requiring anti-infective treatment, including but not limited to tuberculosis, HBV or HCV infection, HIV infection, or CMV infection.\n* Major surgical procedures within the preceding three months.\n* Hypersensitivity or intolerance to Firsekibart; individuals with known hypersensitivity to Chinese hamster ovary (CHO) cell-derived products should also be excluded (Firsekibart is a recombinant monoclonal antibody with potential residual CHO expression risk).\n* Pregnancy, planned pregnancy, or lactation.\n* Use of biological agents within 3 months prior to enrolment, including but not limited to CD20 monoclonal antibodies (e.g., rituximab), B-lymphocyte stimulatory factor inhibitors (e.g., belimumab, telitacicept), or TNF-α inhibitors (e.g., adalimumab, infliximab).\n* Receipt within 3 months prior to enrolment of high-dose glucocorticoids (prednisolone or equivalent ≥60mg qd), plasma exchange, IVIG, or oral\u002Fintravenous cyclophosphamide.\n* Individuals who have received live attenuated vaccines (e.g., varicella, herpes zoster, intranasal influenza vaccines) within 3 months prior to enrolment, or who plan to receive live vaccines during the study period.\n* Any condition deemed by the investigator to potentially prevent the subject from completing the study or pose a significant risk to the subject.",{"count":106,"type":21},15,[54],"Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder in which pro-inflammatory factors of the IL-1 family play a pivotal role in its pathogenesis. In SLE patients, an innate immune hyperreactivity coupled with excessive inflammasome activation leads to substantial IL-1β production, triggering inflammatory phenotypes such as fever and serositis. For SLE patients unresponsive to conventional therapies, particularly those exhibiting high fever and serositis indicative of innate immune overactivation, effective targeted treatments remain scarce. Firsekibart, as a first anti-IL-1β biologic, holds promise in delivering novel therapeutic benefits for SLE patients with high-inflammatory phenotypes who prove refractory to standard therapies.",[110],"Lupus Erythematosus, Systemic","2026-01-26",{"date":113,"type":34},"2026-02-02",{"date":115,"type":21},"2026-04-15",{"date":117,"type":21},"2027-12-31",{"name":40,"class":41},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":42},"100583819","phase-1-vunakizumab-for-the-treatment-of-mild-to-moderate-systemic-lupus-erythematosus-100583819","NCT06881290","Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus","Pilot Study on the Treatment of Vunakizumab in Mild to Moderate Systemic Lupus Erythematosus","Inclusion Criteria:\n\n1. Patients aged 18-65 years meeting the 2019 EULAR\u002FACR classification criteria for SLE.\n2. SLEDAI score was within 2-12 scores (with clinical SLEDAI \\[cSLEDAI\\] ≠ 0).\n3. Occurence of new or recurrent mucocutaneous or joint involvement.\n4. Stable standard treatment regimen prior to study entry but not effect: Prednisone or equivalent corticosteroid dose ≤ 20 mg per day for more than 4 weeks; Immunosuppressant less than 1 type for more than 12 weeks, including methotrexate ≤15 mg per week, azathioprine ≤100mg per day, mycophenolate mofetil ≤1.5 g per day, tacrolimus ≤2 mg per day, cyclosporine ≤150 mg per day). Antimalarials was permitted.\n5. Body mass index (BMI) 18-35 kg\u002Fm² at screening.\n6. Clinically eligible for Vunakizumab combination therapy with corticosteroids after investigator assessment.\n7. Willing to provide written informed consent with demonstrated compliance.\n\nExclusion Criteria:\n\n1. SLE with major organ dysfunction including Encephalopathy\u002Fcognitive impairment, Renal insufficiency, Cardiac insufficiency (NYHA class III-IV), Pulmonary hypertension\u002Finterstitial lung disease\n2. Active SLE-related organ involvement: Lupus cerebritis, Active lupus nephritis (proteinuria ≥1g\u002F24h), Myocardial involvement, Gastrointestinal vasculitis, Diffuse alveolar hemorrhage, Thrombocytopenic purpura, Hemophagocytic syndrome, Retinopathy\n3. Concurrent autoimmune diseases affecting efficacy assessment (e.g., rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis).\n4. Liver dysfunction: ALT\u002FAST \\>1.5×ULN or total bilirubin \\>1×ULN.\n5. Active malignancy within 5 years or history of malignancy.\n6. Comorbidities requiring corticosteroids (e.g., asthma, Crohn's disease).\n7. Active infections requiring treatment:Tuberculosis, HBV\u002FHCV\u002FHIV\u002FCMV infections\n8. Major surgery within 3 months prior to screening.\n9. Hypersensitivity or intolerance to funakizumab.\n10. Pregnancy, lactation, or planned pregnancy.\n11. Biologic therapy within 3 months (anti-CD20 agents, belimumab, TNF-α inhibitors).\n12. Recent intensive therapies: Systemic corticosteroids within 3 months\u002F Plasmapheresis\u002FIVIG\u002Fcyclophosphamide within 3 months\n13. Any condition deemed by investigators to compromise study completion or patient safety.",{"count":97,"type":21},[128],"PHASE1","Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by heterogeneous clinical manifestations ranging from mild cutaneous involvement to severe multi-organ damage. While its pathogenesis involves complex cytokine dysregulation, emerging evidence implicates IL-17 as a potential contributor. Elevated serum IL-17 levels have been observed in SLE patients compared to healthy controls, with heightened expression detected in renal and cutaneous lesions. Ustekinumab, a monoclonal antibody targeting IL-23\u002FIL-12 that indirectly modulates IL-17 signaling, demonstrated superior efficacy and safety to placebo in an SLE clinical trial, particularly in glucocorticoid dose reduction. Notably, no clinical trials have directly evaluated IL-17-targeted therapies for SLE, though case reports suggest secukinumab (an anti-IL-17A agent) may improve cutaneous manifestations in psoriasis-SLE overlap patients.\n\nVunakizumab, a humanized anti-IL-17A monoclonal antibody (IgG1\u002Fκ) with a unique epitope-binding profile, selectively inhibits IL-17A-mediated inflammatory signaling. Its established safety profile and infrequent dosing regimen in IL-17-mediated diseases (e.g., psoriasis, psoriatic arthritis) warrant investigation in SLE. The investigators aim to provide new treatment options for SLE patients",[110],[87,132],"Systemic lupus erythematosus","2025-07-07",{"date":135,"type":34},"2025-07-10",{"date":137,"type":34},"2025-05-19",{"date":139,"type":21},"2027-12-01",{"name":40,"class":41},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":151,"conditions":152,"keywords":153,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":42},"100594007","phase-4-the-efficacy-and-safety-of-deucravacitinib-in-takayasus-arteritis-100594007","NCT07013838","The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis","Comparison of Deucravacitinib and Adalimumab for the Treatment of Relapsed Takayasu's Arteritis: The TYK-TAK Trial","Inclusion Criteria:\n\n* Participants are eligible to be included in the study only if all of the following criteria apply:\n\n  1. Signed Written Informed Consent\n\n     1. Participants fully understand the purpose, nature, method, and possible adverse reactions of the study, willing to consent to the trial and follow study protocol and sign informed consent.\n     2. Participants must have signed an Institutional Review Board (IRB)\u002FIndependent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines. This ICF must be obtained before performing any protocol related procedures that are not part of normal patient care.\n  2. Type of Participant and Target Disease Characteristics\n\n     1. Adult patients (aged 18 or older) fulfilling the 2022 ACR\u002FEULAR classification criteria for TAK.\n     2. Persistence of active disease or relapse despite treatment with GCs combined with a conventional synthetic or biologics immunosuppressive agent other than TNFi.\n     3. Active vasculitis by reader interpretation of FDG-PET at enrollment (by the same reader).\n  3. Reproductive Status The investigator or designee shall counsel women of childbearing potential (WOCBP) and male participants who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy.\n\nWOCBP must have a negative highly sensitive specify: urine or serum as required by local regulations pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of study intervention.\n\nA female is eligible to participate if she is not pregnant or breastfeeding and at least 1 of the following conditions applies:\n\nIs not a WOCBP OR Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\\u003C 1% per year) during the intervention period and for at least 5 half-lives after product administration and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction for the same period.\n\nWOCBP and male participants who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception.\n\nExclusion Criteria:\n\n* Participants are excluded from the study if any of the following criteria apply:\n\n  1. Medical Conditions\n\n     1. Severe disease from TAK for which urgent treatment with interventional procedures or bypass surgery is considered necessary\n     2. Critical organ involvement of TAK, such as myocardial or coronary artery involvement, or cerebral ischemia\n     3. Active hepatitis B or C virus infection, active tuberculosis infection\n     4. Malignancy in the past 5 years (with the exception of fully excised non-melanoma skin cancer or cervical carcinoma in situ)\n  2. Physical and Laboratory Test Findings\n\n     1. Serum liver enzyme tests 3 times higher than the upper limits of normal range\n     2. Estimated glomerular filtration rate ≤ 30 ml\u002Fminute\n  3. Other Exclusion Criteria\n\n     1. Females who are pregnant\n     2. Ever treated with TNFi (including adalimumab) and discontinued due to inadequate response or intolerance.\n     3. Any other sound medical, psychiatric, and\u002For social reason as determined by the investigator",{"count":149,"type":21},50,[54],"This is a 24-week, single-center, randomized, open-label trial conducted by Peking Union Medical College Hospital. The aim of this study is to assess the efficacy and safety of deucravacitinib in adult patients with relapsing TAK in comparison to patients treated with TNF inhibitor (TNFi), the most well-recognized therapeutic choice of non-glucocorticoid immunosuppressive for patients with relapsed or refractory TAK.",[85],[154,155,156,157,158,159],"Deucravacitinib","Adalimumab","Relapsed","Efficacy","Safety","Takayasu arteritis","2025-06-06",{"date":162,"type":34},"2025-06-10",{"date":164,"type":21},"2025-06-15",{"date":166,"type":21},"2028-03-31",{"name":40,"class":41},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":175,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":187,"leadSponsor":189,"locationsCount":42},"100593573","phase-4-telitacicept-for-the-treatment-of-refractory-ra-100593573","NCT07008196","Telitacicept for the Treatment of Refractory RA","An Exploratory Clinical Study on Telitacicept for the Treatment of Refractory Rheumatoid Arthritis","Inclusion Criteria:\n\n1. Fulfill the classification criteria of the 2010 American College of Rheumatology (ACR)\u002FEuropean League Against Rheumatism (EULAR)\n2. Refractory RA definition: Insufficient response to a combination of at least two adequate doses of csDMARDs followed by bDMARDs (including but not limited to tumor necrosis factor inhibitors, interleukin-6 receptor inhibitors, T-cell costimulation molecule inhibitors, B-cell targeted drugs) or tsDMARDs (including but not limited to JAK inhibitors) for 12 weeks, with stable drug dosage for at least 6 weeks\n3. For patients treated with glucocorticoid therapy, they must have been on a stable dose of prednisone or prednisone equivalent ≤ 10 mg\u002Fday for at least 4 weeks before enrollment\n4. For patients treated with non-steroidal anti-inflammatory drugs, they must have been on a stable dose for at least 2 weeks before screening and enrollment\n5. ① Age \\> 18 years and \\\u003C 70 years; ② Absolute neutrophil count ≥ 1.0 × 10⁹\u002FL, platelet count ≥ 100 × 10⁹\u002FL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 3 times the upper limit of normal, total bilirubin within 1.5 times the upper limit of normal, serum creatinine clearance rate \\> 60 ml\u002Fmin; ③ Voluntarily sign the informed consent form\n\nExclusion Criteria:\n\n1. Subjects with other autoimmune diseases\n2. Subjects with severe and poorly controlled cardiovascular, cerebrovascular, respiratory, liver, kidney, gastrointestinal, endocrine, hematological, or neurological diseases, or laboratory abnormalities that, in the opinion of the investigator, pose unacceptable risks for participation in the study\n3. Subjects with a history of malignancy (or less than 5 years since clinical remission)\n4. Subjects who are pregnant or breastfeeding, or plan to become pregnant or start breastfeeding during the study period\n5. Subjects who have received live virus vaccines within 4 weeks prior to enrollment in the study\n6. Subjects allergic to talizumab or any excipients\n7. Subjects who have participated in any other investigational drug trial within 12 weeks prior to the start of this study\n8. Subjects with active hepatitis or a history of severe liver disease at screening\n9. Subjects in the active phase of herpes zoster infection, or those who have experienced severe infections (requiring intravenous antibiotics or hospitalization) within 12 weeks prior to the start of the study medication\n10. Subjects with other conditions deemed unsuitable for enrollment by the investigator",{"count":176,"type":21},30,[54],"This is a single-center, single-arm, open-label, prospective study on the efficacy and safety of Telitacicept in patients with refractory rheumatoid arthritis.",[180],"Rheumatoid Arthritis (RA)",[182,183,60],"Rheumatoid Arthritis","refractory","2025-06-04",{"date":160,"type":34},{"date":162,"type":21},{"date":188,"type":21},"2026-01",{"name":40,"class":41},{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":42},"100584298","chinese-rheumatism-biobankcrb-100584298","NCT06887517","Chinese Rheumatism Biobank(CRB)","Inclusion Criteria:\n\n1. Patients meet the 2012 SLICC classification criteria or 2019 ACR\u002FEULAR classification criteria of SLE.\n2. Disease Duration ≤2 years since SLE diagnosis at baseline\n3. Non-Organ-Threatening Disease, including BILAG-2004 categories A\u002FB\u002FC in neurological, cardiopulmonary, gastrointestinal, ophthalmic, renal, or hematological domains\n\n   Specifically excluded:\n\n   Renal: Cellular casts, hematuria (\\>5 RBC\u002Fhpf), proteinuria (\\>0.5g\u002F24hr), pyuria (\\>5 WBC\u002Fhpf), or biopsy-proven lupus nephritis Neuropsychiatric: Seizures, psychosis, organic brain syndrome, cerebrovascular events Cardiopulmonary: Pulmonary arterial hypertension, myocarditis, pulmonary hemorrhage Vasculitis: Ulcerative\u002Fnecrotizing lesions or biopsy-proven vasculitis Hematologic: Hemolytic anemia, thrombocytopenia (\\\u003C100×10⁹\u002FL) No acute thromboembolic events within 3 months\n4. Treatment History:\n\n   No systemic corticosteroids, plasmapheresis, or IVIG within 3 months No biologics (e.g. belimumab, TNF-α inhibitors) within 3 months No cyclophosphamide or CD20 inhibitors within 6 months\n5. Disease Activity: Clinical SLEDAI-2K \\>0 at screening\u002Fbaseline\n\nExclusion Criteria:\n\n1. SLE with coexisting other autoimmune or autoinflammatory diseases, including but not limited to rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis.\n2. SLE with concurrent conditions requiring glucocorticoid therapy, such as asthma or Crohn's disease.\n3. Pregnancy, planned pregnancy, or lactation.\n4. SLE with major organ dysfunction at baseline , including: impaired consciousness or cognitive decline, renal insufficiency, cardiac insufficiency (NYHA Class 3 or 4), pulmonary hypertension or interstitial lung disease, uncontrolled infections\n5. Inability to ensure compliance with long-term follow-up\n6. Any condition deemed by investigators to compromise trial completion or pose significant risks",{"count":197,"type":21},300,"OBSERVATIONAL","Early prediction of major organ damage in SLE needs to dynamically track the evolution of SLE patients before and after the onset of major organ damage, and analyze the microscopic molecular evolution patterns synchronized with the macroscopic pathophysiological changes.",[110],[202,203,204],"systemic lupus erythematosus","major organ damage","progress of disease","2025-04-07",{"date":207,"type":34},"2025-04-09",{"date":209,"type":34},"2025-02-10",{"date":211,"type":21},"2033-04-01",{"name":40,"class":41},{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":42},"100509696","phase-4-effectiveness-of-mycophenolate-mofetil-combined-with-tacrolimus-for-steroid-tapering-in-systemic-lupus-erythematosus-100509696","NCT05916781","Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus","Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus: A Prospective, Random Control, Open-label, Single Center Clinical Trial","Inclusion Criteria:\n\n* Systemic lupus erythematosus participants diagnosed with 2019 American College of Rheumatology\u002FEuropean League Against Rheumatism (ACR\u002FEULAR) classification criteria, fulfilled with American College of Rheumatology (ACR) lupus nephritis definition, and have reached treatment target (accord with lupus nephritis clinical remission and DORIS) for at least 6 months. The target is defined as: (1)24h urine protein ≤0.5g\u002Fd；(2)stable of improved renal function (baseline creatinine ±10% or decrease 15%)；(3)clinical SLE Disease Activity Index (cSLEDAI) =0 (all scores are required zero, except hypocomplementemia and anti-dsDNA antibody positivity)；(4)PGA score (Physician Global Assessment)\\\u003C0.5; (5)prednisone or equivalent steroid dose≤5mg\u002Fd；(6)stable use of immunosuppressants and antimalarial drugs; (7)no use of biological agents.\n* According to the physician, the participant can accept this treatment.\n* The participant is willing to join this clinical trial, has good compliance, and could understand and sign the informed consent before the study begins.\n\nExclusion Criteria:\n\n* SLE complicated with important organ dysfunction, including consciousness disorder, cognitive disorder, renal dysfunction, heart dysfunction (NYHA class 3, 4), pulmonary arterial hypertension, and interstitial lung disease.\n* SLE with active vital organ disease (not satisfied with DORIS), including but not limited to active neuropsychiatric systemic lupus erythematosus, lupus nephritis, thrombocytopenia, hemolytic anemia, myocardial involvement, gastrointestinal involvement, etc.\n* Participants who are allergic to or intolerant with mycophenolate mofetil or tacrolimus.\n* Participants with acute and chronic infections requiring anti-infective treatment, including but not limited to tuberculosis infection, Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infection, Human Immunodeficiency Virus (HIV) infection, and Cytomegalovirus (CMV) infection.\n* Participants who are pregnant or planning to become pregnant.\n* Participants who have used biological agents within 6 months before enrollment.\n* The researcher considers any condition that may cause the participant to be unable to complete the study or bring an obvious risk to the participant.",{"count":221,"type":21},220,[54],"The goal of this clinical trial is to determine whether mycophenolate mofetil(MMF) combined with tacrolimus(TAC) can maintain remission in patients with lupus nephritis (LN) who have reached treatment targets after steroid tapering. The main question\\[s\\] it aims to answer are:\n\n* The efficacy, safety and tolerability of MMF combined with TAC regimen in the treatment of LN patients in the maintenance period.\n* The influence of low-dose steroid on carotid intima thickness (CIMT).\n* The omics and cell-free RNA (cfRNA) spectral differences related to lupus flare.\n* The differences in health economics between steroid tapering and steroid maintenance patients.\n\nParticipants will be randomly assigned into 2 groups. In the steroid tapering group, participants will take MMF+TAC treatment without steroid for 1 year, and participants who stop steroid treatment without lupus flare will be randomly assigned to monotherapy with MMF or TAC. In the steroid maintenance group, participants will take MMF+TAC+steroid for 1 year, and participants without lupus flare will stop the use of steroid for 6 months. Participants without lupus flare after the stop of steroid will be randomly assigned to monotherapy with MMF or TAC.",[28,225],"Lupus Nephritis",[227,228,229,202,230],"mycophenolate mofetil","tacrolimus","steroid tapering","lupus nephritis","2024-07-08",{"date":233,"type":34},"2024-07-09",{"date":235,"type":34},"2023-07-01",{"date":237,"type":21},"2026-07-31",{"name":40,"class":41},{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":246,"sex":16,"minAge":247,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":42},"100528930","exploring-biomarkers-for-therapeutic-response-of-lupus-nephritis-based-on-multi-omics-analysis-100528930","NCT06167174","Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis","Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics","Inclusion Criteria:\n\n1. Age between 16-60 years.\n2. Fulfilling the 2012 SLICC classification for SLE.\n3. Renal biopsy pathology was clearly classified as III \\\\ IV \\\\ V+III \\\\ V+IV within 6 months.\n4. Renal biopsy reveals active disease.\n5. 24-hour urinary protein was tested twice within two weeks, both of which were greater than 1g.\n6. The patients have never received glucocorticoid\u002Fimmunosuppressants or received standard treatment for more than 1 month without change. The standard treatment should fulfill: a. prednisone 0-20mg\u002Fday, or equivalent other glucocorticoids; b. acceptable immunosuppressants, including Tacrolimus ≤ 4mg\u002Fd, methotrexate ≤ 15mg\u002Fweek, azathioprine ≤ 100mg\u002Fd and MMF ≤ 1g\u002Fd.\n7. Informed consent obtained.\n\nExclusion Criteria:\n\n1. Other concomitant connective tissue diseases or autoimmune diseases.\n2. Neuropsychiatric lupus, alveolar hemorrhage, retinal lesions, pulmonary arterial hypertension, or other severe organ involvement.\n3. Pregnant or lactating women.\n4. Current infections that require antibiotic or antiviral treatment.\n5. Other kidney diseases.\n6. Platelet \\\u003C 50×10\\^9\u002FL.\n7. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) that is greater than 1.5 times the upper limit of the normal value.\n8. Total bilirubin or blood lipid that is greater than 2 times the upper limit of the normal value.\n9. Other conditions that not suitable for inclusion in the study, assessed by the investigators.",true,"16 Years","60 Years",{"count":250,"type":21},100,"This is an observational study of patients with lupus nephritis aiming to find biomarkers that can predict patients' response to immunosuppressants. We planed to collect 100 lupus nephritis patients' peripheral blood,kidney tissues and urine before and after treatment (mycophenolate mofetil or cyclophosphamide, in combination with glucocorticoids). Then multi omics analysis, including single cell RNA-seq, ATAC-seq and CITE-seq, will be performed to find new biomarkers for patients' response and prognosis.",[225],[225],"2023-12-04",{"date":256,"type":34},"2023-12-12",{"date":258,"type":21},"2023-12-05",{"date":260,"type":21},"2028-12-05",{"name":40,"class":41},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":269,"targetDuration":4,"studyType":22,"phases":271,"briefSummary":272,"conditions":273,"keywords":276,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":42},"100513424","phase-4-efficacy-and-safety-for-telitacicept-in-the-remission-maintenance-treatment-of-anca-associated-vasculitis-ttcazarem-100513424","NCT05965284","Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)","A Prospective, Open-label, Controlled, Single Center Clinical Study of the Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis","Inclusion Criteria:\n\n1. Patients age 18 to 65 years, both genders can be included.\n2. Patients who are newly diagnosed or relapsing granulomatosis with polyangiitis or microscopic polyangiitis must fulfill the 2022 ACR\u002FEULAR classification criteria of GPA or MPA.\n3. Patients who are in complete remission after combined treatment with glucocorticoids and Rituximab. Remission is defined as a Birmingham Vasculitis Activity Score (BVAS version 3) of 0. And the daily dosage of prednisone are no more than 10mg (or equivalent).\n4. Patients have to be ANCA-positive at diagnosis or during the course of their disease.\n\nExclusion Criteria:\n\n1. Patients with TPMT gene mutation.\n2. Patients who had been treated with either AZA but relapsed in the past.\n3. Patients who had been treated with either AZA but had to stop due to adverse events or intolerance.\n4. Patients who have planned for pregnancy in next 1.5 years.\n5. Patients with severe liver dysfunction(defined as the 2-folds elevation of normal upper limit or Child grade III), heart failure or ESRD(eGFR\\\u003C30ml\u002Fmin).\n6. Patients with uncontrolled sever hypertension, diabetes, active bacteria or fungal infection;\n7. Patients with active hepatitis virus infection as well as patients who have active mycobacteria infection;\n8. Patients who had other autoimmune diseases.\n9. Patients with malignancy.\n10. Patients who are not eligible according to the judge of the principal investigators or site investigators.",{"count":270,"type":21},40,[54],"This study is a prospective, open-labelled, randomized, controlled, single-center clinical trial. The aim of this study is to compare the remission rate of patients treated with Telitacicept combined with azathioprine and azathioprine alone in remission-maintenance treatment of AAV.",[274,275],"ANCA-associated Vasculitis","Maintenance Therapy",[274,60,277,278],"Azathioprine","Relapse rate","2023-07-20",{"date":281,"type":34},"2023-07-28",{"date":283,"type":34},"2023-03-09",{"date":285,"type":21},"2026-12-31",{"name":40,"class":41},{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":295,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":308,"locationsCount":42},"100513236","phase-4-efficacy-and-safety-for-rituximab-combined-with-telitacicept-in-the-treatment-of-anca-associated-vasculitis-ttcaavrem-100513236","NCT05962840","Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)","A Prospective, Randomized, Single-blinded Placebo-controlled, Single Center Clinical Study of the Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis","Inclusion Criteria:\n\n1. Patients age 18 to 65 years, both genders can be included.\n2. Patients who are newly diagnosed or relapsing granulomatosis with polyangiitis or microscopic polyangiitis must fulfill the 2022 ACR\u002FEULAR classification criteria of GPA or MPA.\n3. Patients have severe active AAV according to the 2021 ACR\u002Fvasculitis foundation definition.\n4. Patients have to be PR3-ANCA-positive at diagnosis or during the course of their disease.\n\nExclusion Criteria:\n\n1. Patients who had been treated with Rituximab but had to stop due to adverse events or intolerance.\n2. Patients who had other autoimmune diseases.\n3. Patients with severe liver dysfunction (defined as the 2-folds elevation of normal upper limit or Child grade III), heart failure or ESRD (eGFR\\\u003C30ml\u002Fmin).\n4. Patients who are pregnant or have planned for pregnancy in next 2 years.\n5. Patients with uncontrolled sever hypertension, diabetes, active bacteria or fungal infection.\n6. Patients with active hepatitis virus infection as well as patients who have active mycobacteria infection.\n7. Patients with malignancy.\n8. Patients who are not eligible according to the judge of the principal investigators.",{"count":270,"type":21},[54],"This study is a prospective, open-labelled, randomized, controlled, single-center clinical trial. The aim of this study is to investigate the remission rate of patients treated with Telitacicept combined with Rituximab in remission-induction and Telitacicept alone in remission-maintain treatment.",[298],"ANCA Associated Vasculitis",[60,300,301],"relapse rate","remission maintain treatment","2023-07-19",{"date":304,"type":34},"2023-07-27",{"date":306,"type":34},"2023-06-29",{"date":285,"type":21},{"name":40,"class":41},""]